Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors
Joana Lima Ferreira, Cláudia Costa, Bernardo Marques, et al.
Cancer Immunology Immunotherapy (2020) Vol. 70, Iss. 2, pp. 299-309
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Immune checkpoint inhibitors in melanoma
Matteo S. Carlino, James Larkin, Georgina V. Long
The Lancet (2021) Vol. 398, Iss. 10304, pp. 1002-1014
Open Access | Times Cited: 825
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
Eystein S. Husebye, Frédéric Castinetti, Sherwin Criseno, et al.
European Journal of Endocrinology (2022) Vol. 187, Iss. 6, pp. G1-G21
Open Access | Times Cited: 79
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis
Yee-Ming Melody Cheung, Wei Wang, Bradley A. McGregor, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 8, pp. 1795-1812
Open Access | Times Cited: 56
Thyroid disorders induced by immune checkpoint inhibitors
Dimitra Karaviti, Eleni-Rafaela Kani, Eleftheria Karaviti, et al.
Endocrine (2024) Vol. 85, Iss. 1, pp. 67-79
Open Access | Times Cited: 11
Case report: Diagnosis of impaired consciousness in a cancer patient using immune checkpoint inhibitors
Daniel Cathalifaud, Cristóbal Basáez, T Keituqwa Yáñez
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function
Karen Tsai, Huiyan Ma, Tom Z. Liang, et al.
Thyroid (2024) Vol. 34, Iss. 2, pp. 158-166
Closed Access | Times Cited: 7
Immune Related Adverse Events of the Thyroid – A Narrative Review
Christopher A. Muir, Venessa Tsang, Alexander M. Menzies, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 28
Thyroid-related adverse events induced by immune checkpoint inhibitors
Alexandra Chera, Andreea Lucia Stancu, Octavian Bucur
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 27
Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study
Lingge Wu, Yan Xu, Xiang Wang, et al.
Endocrine (2023) Vol. 81, Iss. 1, pp. 123-133
Open Access | Times Cited: 14
Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients
Han-Sang Baek, Chaiho Jeong, Kabsoo Shin, et al.
BMC Endocrine Disorders (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 21
Correlative analysis of immune-related thyroid dysfunction and prognosis in patients with advanced esophageal squamous cell carcinoma
Liangshan Da, Ziting Qu, Yiyin Zhang, et al.
Anti-Cancer Drugs (2025)
Closed Access
Thyroid Dysfunction as a Predictor of PD-1/PD-L1 Inhibitor Efficacy in Advanced Lung Cancer
Yanling Wang, Xiaoping Ma, Jia Ma, et al.
Research Square (Research Square) (2025)
Closed Access
Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
Yanling Wang, Xiaoping Ma, Jia Ma, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
Nicia I. Profili, Roberto Castelli, Antonio Gidaro, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 15, pp. 5161-5161
Open Access | Times Cited: 10
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
Calogera Claudia Spagnolo, G Giuffrida, Salvatore Cannavò, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 246-246
Open Access | Times Cited: 15
Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
Young Shin Song, Hannah Yang, Beodeul Kang, et al.
Liver Cancer (2023) Vol. 13, Iss. 1, pp. 89-98
Open Access | Times Cited: 9
Immune-related thyroid dysfunctions during anti PD-1/PD-L1 inhibitors: new evidence from a single centre experience
Alice Nervo, Matteo Ferrari, Giovanni Gruosso, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 8, pp. 4817-4824
Closed Access | Times Cited: 8
Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort
Angelica D’Aiello, Juan Lin, Rasim Gucalp, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1464-1464
Open Access | Times Cited: 18
Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center
Rosaria Maddalena Ruggeri, Calogera Claudia Spagnolo, A. Alibrandi, et al.
Journal of Endocrinological Investigation (2023) Vol. 46, Iss. 11, pp. 2399-2409
Closed Access | Times Cited: 7
Endocrine toxicity of cancer immunotherapy: clinical challenges
Bliss Anderson, Daniel L. Morganstein
Endocrine Connections (2021) Vol. 10, Iss. 3, pp. R116-R124
Open Access | Times Cited: 17
Immune-related thyroid dysfunction in patients with non-small cell lung cancer
Cuihong Cai, Shuangshuang Zhou, Jingjing Qu, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 1, pp. 253-263
Open Access | Times Cited: 2
Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers
Anupam Kotwal, Mabel Ryder
Current Opinion in Endocrinology Diabetes and Obesity (2021) Vol. 28, Iss. 5, pp. 517-524
Closed Access | Times Cited: 13
Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study
Hanna J. Lee, Anjali Manavalan, Mihaela Stefan–Lifshitz, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 4
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group
Maria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, et al.
Cancer Treatment Reviews (2024) Vol. 126, pp. 102734-102734
Open Access | Times Cited: 1
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study
Stine K. Christensen, Mette Lerche Winther, Ida J. Laursen, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 5
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top